When patients were grouped by NPAS3 expression above and below the median value, there was a trend toward correlation of increased BCR-free survival with higher NPAS3 expression in two independent prostate cancer microarray datasets (Fig. 2A,B)6, 7. This evidence concerns the gene BCR and prostate cancer.